Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments

Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.

Research & Development Strategy

Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets

Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.

Companies Clinical Trials

Belgium's Sequana Sits At Junction Between Pharma And Medtech

The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.

Cardiovascular Business Strategies

Xarelto Declines Are New Normal At Bayer

Sales of the blockbuster Factor Xa blood thinner Xarelto declined more steeply than was expected but Bayer’s second biggest seller Eylea is still performing well.

Sales & Earnings Business Strategies

AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks

Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra. 

Clinical Trials Rare Diseases

GSK And Takeda Boost Arrowhead’s Coffers, But In-House Results Crucial To Gene Silencing Platform

Arrowhead is expecting a flurry of early-stage results from its in-house pipeline, including in lung diseases, where gene silencing platforms have so far struggled to reach, as it banks two recent milestone payments.

Cardiovascular Respiratory

Boehringer To Profit From Jardiance Well Into Second Half Of Decade

The German firm is anticipating a major label expansion in kidney disease for its SGL2 inhibitor later this year, prompting Boehringer to gear up commercial activities as AstraZeneca’s rival Farxiga faces the threat of generic competition.

Sales & Earnings Renal

Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances

Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

Scrip Asks Research & Development

Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success

Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.

Clinical Trials Cardiovascular

Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping

Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.

Cardiovascular Clinical Trials

BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones

Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

Clinical Trials Strategy

Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.

Cardiovascular Business Strategies
See All
UsernamePublicRestriction

Register